Roche/Genentech Keeps Commitment To External Cancer Innovation
Interview: Oncology Partnering’s Don O’Sullivan, Genentech R&D’s Shiva Malek
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
You may also be interested in...
In this week's podcast version of Five Must-Know Things, hear about Roche's deal-making in a pandemic, coronavirus vaccine disinformation, Amgen’s Five Prime acquisition, a Novartis clinical trial failure, and new data for a Merck antiviral for the coronavirus.
Plus deals involving AbbVie/Mitokinin, Roivant/Silicon Therapeutics, CASI/Cleave Therapeutics, Tallac/ALX Oncology, AgeX/LyGenesis, Chinook/Evotec and more.
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.